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Tγδ and B1 lymphocytes are essential components of the mucosal immune system, acti-
vated directly by different bacterial and viral ligands without additional costimulatory signals
and preprocessing of other immune effectors. This ability enables the immune system
to provide rapid protection against pathogens and contributes to the decoding mecha-
nism of the sensitizing activity of mucosal antigens. The early interaction of these cells
results in the production of antibodies of immunoglobulin M (IgM) and IgA isotypes, but
not immunoglobulin E (IgE). We studied the subcutaneous, intranasal, and oral delivery as
three major routes of potential entry for antigens of opportunistic microorganisms, using
the immunomodulator Immunovac-VP-4, which is able to activateTγδ and B1 lymphocytes.
The subcutaneous and intranasal routes produced a significant increase of these cells in
lymph nodes associated with the nasal cavity (NALT) and in those associated with bronchial
tissue (BALT). The oral route significantly increased levels of these cells in the spleen, in
NALT, BALT, and in nodes associated with the gut (GALT).We found that mucosal application
of Immunovac-VP-4, which contains antigens of conditionally pathogenic microorganisms,
in conjunction with the activation of Tγδ and B1, induces adaptive immune mechanisms
not only in the lymphoid formations associated with the respiratory system and with GALT,
but also in the spleen [increased expression of cluster of differentiation 3 (CD3), CD4, CD8,
CD19, and CD25].This indicates that there is migration of lymphoid cells from the regional
lymph nodes and mucosal lymphoid tissues via the lymph and blood to distant organs,
resulting in lymphoid development, and both local and systemic immunity. Mucosal appli-
cation of Immunovac-VP-4 in mice potentiates the cytotoxic activity of NK cells in the NALT,
BALT, and GALT.The highest cytotoxicity was observed in cells, derived from lymphoid tis-
sue of the intestine after oral immunization. Although we found that cytokine production
was increased by all three immunization routes, it was most intensive after subcutaneous
injection. Our findings confirm that there is an intensive exchange of lymphocytes not
only between lymphoid formations in the mucous membranes of the respiratory tract and
of GALT, but also with the spleen, which means that if effective mucosal vaccines are
developed, they can induce both local and systemic immunity.
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INTRODUCTION
Theoretical and experimental studies have shown that the main
components of the mucosal immune system (MIS), determin-
ing the particular features of functional activity, are Tγδ lym-
phocytes and B1 cells in the epithelial mucosa, which have the
ability to detect pathogen-associated molecular patterns (PAMPs)
without costimulator signals and preliminary processing by other
effectors cells (1–4). The MIS is also activated by other immuno-
competent cells, which interact with Tγδ and B1 lymphocytes,
resulting in stimulation of both local and systemic immunity in
response to antigens (4, 5). Pattern-recognition receptors, Toll-like
receptors (TLRs) recognize PAMPs of various pathogen classes,
interact with cellular adaptive systems, and trigger the cascade of
various signaling pathways to induce the complex of protective
reactions (6–8).
The importance of such studies is obvious, yet the molecu-
lar and cellular mechanisms of innate and adaptive immunity
activation in response to mucosal application of immunomod-
ulators and vaccines have not been well investigated. Therefore,
we conducted a study of mucosal immunity parameters, using
the bacterial poly-component vaccine Immunovac-VP-4, which
contains a wide panel of PAMPs. Various experimental models
have shown the immunostimulatory effects of Immunovac-VP-
4 (9, 10).
Bacterial poly-component vaccine Immunovac-VP-4 (Federal
State Department, Science and Production Association, Micro-
gene, Russia), created from the antigens of opportunistic microor-
ganisms (Klebsiella pneumoniae, Proteus vulgaris, Escherichia coli,
and Staphylococcus aureus), was designed for use in immunother-
apy for chronic inflammatory and allergic diseases. The vaccine
contains lipopolysaccharide associated with the outer-membrane
proteins of the Gram-negative bacteria, peptidoglycan, teichoic
acids, and lipoproteins of S. aureus, which are the ligands of
TLRs 1/2, 4, 5/6, 9, revealed on cell line 293 [embryonic cells
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of human kidney, transformed by the E1 region of human
adenovirus (11)].
MATERIALS AND METHODS
EXPERIMENTAL ANIMALS
CBA mice, weighing 16–18 g, were obtained from the Scientific
Center of Biomedical Technologies of the Russian Academy of
Medical Science (Andreevka, Russia), and kept in the vivarium
of the Metchnikov Research Institute for Vaccine and Sera at the
Russian Academy of Medical Science. The housing,husbandry,and
sacrificing conditions conformed to European Union guidelines
for the care and use of laboratory animals.
MICE IMMUNIZATION
For immunization, we used the bacterial poly-component vac-
cine Immunovac-VP-4, which contains antigens of condition-
ally pathogenic microorganisms (E. coli, P. vulgaris, S. aureus, K.
pneumoniae).
Mucosal immunization was performed as follows: for intranasal
immunization, the vaccine was applied in the nares in a single
dose (an average of 500µg in 30µL). For oral immunization, the
average single dose was 2000µg/0.5 mL. Subcutaneously, the vac-
cine was administered twice within a 7-day interval at a dose of
200µg (in 0.5 mL) for each injection. Twenty-four hours after
the last vaccine administration, the mice were sacrificed using
ether. The spleens, lymph nodes associated with the nasal cav-
ity (NALT), nodes associated with bronchial tissue (BALT), and
nodes associated with the gut (GALT) were analyzed and the num-
ber and phenotype of mononuclear cells expressing TLRs in the
immunized mice were determined.
ISOLATION OF MONONUCLEAR LEUKOCYTES
Mononuclear leukocytes were obtained from lymphoid organs
using Ficoll-Paque PLUS (GE Healthcare, USA) (12).
Quantitation of surface markers and TLRs was conducted using
monoclonal antibodies (Caltag Laboratories, Carlsbad, CA, USA)
against corresponding antigens, via flow cytometry (FACSCal-
ibur). For the mononuclear lymphocytes from the spleens, lymph
nodes, and intestinal nodes, we determined the level of expression
for cluster of differentiation 3 (CD3), natural killer 1.1 (NK1.1),
CD3/NK, CD4, CD25, CD4/CD25, CD8, CD19, major histocom-
patibility complex (MHC) class II, CD5.2, T-cell receptor Tγδ,
TLR2, TLR4, and TLR9.
NATURAL KILLER CELL ACTIVITY
Cytotoxic activity of mononuclear leukocytes from the lym-
phoid organs was determined using the NK-dependent tumor
cell line K-562. Tumor cells (3× 104/mL) were incubated in
culture medium (RPMI-1640, containing 2 mM glutamine, 5%
v/v fetal calf serum, and 1% v/v benzylpenicillin sodium salt)
with mononuclear leukocytes in a proportion of 1:5 in flat-
bottomed 96-well plates for 18 h in a humidified incubator
set at 37°C and 4% CO2. Next, vital dye MTT (Sigma) was
added to the wells, the optical density at wavelength λ 540 nm
was measured on a Multiscan MS (Labsystem, Helsinki, Fin-
land), and the percentage of lysed tumor cells (cytotoxicity) was
calculated.
SUBPOPULATIONS OF LYMPHOCYTES
Subpopulations of lymphocytes were identified by flow cytometry
using antibodies from Caltag Laboratories (Invitrogen, Carlsbad,
CA, USA). The cells were washed in cold phosphate-buffered saline
(PBS) and were stained with antibodies conjugated to fluorescein
isothiocyanate and to phycoerythrin according to the manufac-
turer’s instructions. The suspension was then washed twice in cold
PBS. The results were measured with a flow cytometer (FACSCal-
ibur, Becton, Dickinson and Company, Franklin Lakes, NJ, USA).
The cell population gate was determined by front and side light-
scattering and cell size; there were 5000 cells per gate. Statistical
analyses were performed with WinMDI (version 2.8; Microsoft,
Redmond, WA, USA).
DETERMINATION OF CYTOKINE LEVELS
Cytokine levels in the blood sera of mice were determined
by immunoassay (Bender MedSystems, San Diego, CA, USA)
according to the manufacturer’s instructions.
STATISTICAL EVALUATION
All experiments were repeated at least three times. To study
whether there is a general difference between three groups, first
ANOVA test was performed, followed by Bonferroni post hoc test
to compare specific groups or the Mann–Whitney U t -test was
used to compare two individual groups. P values (M ±m) <0.05
were considered significant.
RESULTS
EXPRESSION OF TLRs
The level of TLR expression in the lymphoid organs of the control
mice, based on data from three experiments, was low (0.01–0.5%)
(Figure 1). It is important to note that in two trials, almost identi-
cal results were obtained, which may be considered normal values
for non-immunized mice.
In the mice vaccinated once intranasally, the number of cells
expressing TLRs did not increase significantly (Figure 1). After a
single oral administration of the vaccine, there was a significant
(p< 0.05) increase of TLR4 and TLR9 in the GALT (5.2± 0.5%
and 4.6± 0.3%, respectively) and of TLR9 (1.2± 0.3%) in NALT–
BALT. There were no significant changes in TLR levels in the spleen
using this route of vaccine administration.
The distribution of TLRs for a single subcutaneous injection of
200µg of the vaccine differed. The level of TLR2 (3.4± 0.3%) and
TLR4 (1.2± 0.06%) in the spleen increased significantly (p< 0.05)
to 1± 0.04% and 1.58± 0.06%, respectively. Also, the levels of
TLR2, TLR4, and TLR9 in the NALT–BALT increased after subcu-
taneous vaccine administration. However, there were no changes
in the level of TLRs in the GALT.
Toll-like receptors expression in tissue after three administra-
tions was more significant. It was lowest in intranasal immu-
nization, but TLR4 expression in the NALT–BALT increased to
1.43± 0.09%,while TLR9 expression in the NALT–BALT increased
to 1.27± 0.17%, and TLR9 expression in the GALT increased
to 1.2± 0.15% (Figure 2). After oral administration, the highest
expression of TLR4 and TLR9 occurred in the GALT: 13± 1.62%
and 14.9± 1.5%, respectively. In the NALT–BALT, the values were
1.9± 0.32% and 2.95± 0.65%, respectively. It is worth noting that
the level of TLR9 also increased in the spleen to 3.47± 0.9%.
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FIGURE 1 |The level ofToll-like receptors (TLRs) by route of vaccine
administration, after one application. The stippled line indicates the
maximum levels of TLR expression in control (non-immunized) mice
(n=10 in each group). Spleen: nasal/oral admin. TLR2,3,9 p>0.05;
nasal/subcut. admin. TLR2 p<0.01; TLR4 p<0.05; TLR9>0.05,
oral/subcut. admin. TLR2 p<0.01; TLR4 p<0.05. NALT/BALT :
nasal/oral admin. TLR2,4 p>0.05; TLR9 p< 0.05; nasal/subcut. admin.
TLR2,3,4 p< 0.05; oral/subcut. admin. TLR2,4 p<0.05, TLR9 p>0.05.
GALT : nasal/oral admin. TLR2 p>0.05; TLR4,9 p<0.001; nasal/subcut.
admin. TLR2,3,4 p>0.05; oral/subcut. admin. TLR2 p>0.05, TLR4,9
p< 0.001. *p<0.05 compared with control group (Mann–Whitney U
t -test).
FIGURE 2 |The level ofToll-like receptors (TLRs) after three vaccine
applications via the mucosa and after two subcutaneous injections. The
stippled line indicates the maximal levels of TLR expression in control
(non-immunized) mice (n=10 in each group). Spleen: nasal/oral admin.
TLR2,3 p>0.05, TLR9 p<0.01; nasal/subcut. admin. TLR2 p< 0.01; TLR4
p<0.05; TLR9>0.01, oral/subcut. admin. TLR2 p<0.01; TLR4 p<0.05, TLR9
p> 0.05. NALT/BALT : nasal/oral admin. TLR2 p>0.05; TLR4 p<0.05; TLR9
p< 0.01; nasal/subcut. admin. TLR2,3,4 p<0.001; oral/subcut. admin.
TLR2,4,9 p<0.001. GALT : nasal/oral admin. TLR2 p>0.05; TLR4,9 p< 0.001;
nasal/subcut. admin. TLR2,3,4 p>0.05; oral/subcut. admin. TLR2 p>0.05,
TLR4,9 p< 0.001. *p<0.05 compared with control group (Mann–Whitney U
t -test).
There were almost no changes in the level of TLR2 in the inves-
tigated organs following mucosal immunization. Subcutaneous
immunization differed in several ways from mucosal immuniza-
tion. First, the subcutaneous method increased the expression of
TLR2, TLR4, and TLR9 not only in the spleen, but also in the
NALT–BALT by 11.2–13.2%. Second, the level of expression of
these three receptors was lowest in the intestinal mucosa, only
slightly exceeding the values for non-immunized mice. Third,
TLR2 was found in significant amounts only after subcutaneous
administration.
IMMUNOPHENOTYPING OF THE CELLS
The dynamics of lymphocyte immunophenotypes in mice spleens,
NALT–BALT, and GALT was investigated. Table 1 presents data on
the markers activated, by immunization route and tissue type,
in control (non-immunized) mice, versus mice immunized with
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Table 1 | Activation of leukocytes by immunization method and tissue type.
Method of
immunization
Level of leukocyte markers (M ±m %)a
Spleen NALT–BALT GALT
Marker Intact Immunized Marker Intact Immunized Marker Intact
Intranasally:
three times
CD3 6.3 ± 0.61 47.4 ± 4.1 (7) CD3 1.2 ± 0.6 7.6 ± 0.3 (6.4) CD3 0.3 ± 0.16 2.7 ± 0.06 (9.0)
CD3/NK 1.13 ± 0.65 3.63 ± 0.17 (3) CD3/NK 0.4 ± 0.6 1.19 ± 0.16 (3) CD4 0.34 ± 0.15 1.9 ± 0.02 (5.6)
CD4 2.1 ± 1.2 58.6 ± 1.8 (28) CD4 3.5 ± 0.8 13.7 ± 1.1 (3.9) CD8 0.24 ± 0.09 3 ± 0.03 (12.5)
CD4/CD25/
Foxp3
0.8 ± 0.26 4.48 ± 1.1 (5.6) MHCII 1.6 ± 0.4 72.0 ± 4.5 (45) B1 0.15 ± 0.06 0.53 ± 0.03 (3.5)
CD8 4.7 ± 0.74 34.2 ± 4.6 (7.3) CD19 0.63 ± 0.2 25.2 ± 1.5 (39)
Tγδ 0.17 ± 0.02 2.8 ± 1.1 (16) Tγδ 0.05 ± 0.02 1.6 ± 0.06 (32)
B1 0.08 ± 0.03 0.9 ± 0.02 (11.3) B1 0.21 ± 0.15 1.7 ± 0.06 (8)
Orally: three
times
CD3/NK 1.13 ± 0.65 5.8 ± 0.6 (5.2) CD3 1.2 ± 0.6 34 ± 5.5 (28) CD3 0.3 ± 0.16 4.3 ± 0.9 (14)
CD4 2.1 ± 0.2 13.3 ± 1.3 (6) CD4 3.5 ± 0.8 40.1 ± 3.1 (11) NK 0.7 ± 0.03 33.3 ± 1.2 (46)
CD25 1.6 ± 0.65 12.6 ± 0.8 (7.8) CD8 1.8 ± 0.08 31.9 ± 5.1 (17) CD4 0.34 ± 0.15 7.3 ± 1.1 (21)
CD4/CD25/
Foxp3
0.8 ± 0.2 2.44 ± 0.04 (3) CD19 0.6 ± 0.2 8.2 ± 0.6 (13) CD25 0.7 ± 0.16 5.4 ± 0.5 (7.6)
Tγδ 0.17 ± 0.02 1.43 ± 0.1 (3.7) MHCII 1.6 ± 0.4 4.8 ± 0.8 (3) CD8 0.24 ± 0.09 2.2 ± 0.15 (10)
B1 0.08 ± 0.03 0.5 ± 0.06 (6.2) Tγδ 0.05 ± 0.02 9.3 ± 1.8 (186) CD19 0.4 ± 0.1 39.9 ± 0.8 (97)
B1 0.21 ± 0.15 2 ± 0.3 (9.4) CD3/NK 1.1 ± 0.16 13.7 ± 0.9 (12)
MHCII 5.0 ± 0.9 51.7 ± 1.0 (10)
Tγδ 0.2 ± 0.1 9.0 ± 0.8 (45)
B1 0.15 ± 0.06 11.7 ± 0.9 (117)
Subcutaneously:
two times
CD3 1.2 ± 0.6 10.4 ± 1.2 (8.8) CD3 0.3 ± 0.16 2.4 ± 0.2 (8.8)
CD4 2.1 ± 1.2 14.3 ± 2.26 (7) CD4 3.5 ± 0.8 12.6 ± 1.0 (3.5) CD4 0.34 ± 0.15 1.9 ± 0.16 (5.5)
CD25 1.6 ± 0.15 5.6 ± 0.57 (3.5) CD8 1.8 ± 0. 12.4 ± 1.9 (7) CD8 0.24 ± 0.09 1.5 ± 0.2 (6)
CD4/CD25/
Foxp3
0.8 ± 0.26 2.8 ± 0.14 (3) CD19 0.6 ± 0.02 2.3 ± 0.12 (3.5) MHCII 5.16 ± 0.9 25.9 ± 0.7 (5)
Tγδ 0.17 ± 0.02 5.3 ± 0.5 (31.2) Tγδ 0.05 ± 0.02 12.0 ± 1.6 (240) CD19 0.4 ± 0.1 1.75 ± 0.2 (4.3)
B1 0.08 ± 0.03 4.9 ± 1.2 (62) B1 0.2 ± 0.15 12.2 ± 1.6 (58)
aData are shown only for instances when marker levels increased by at least threefold.
BALT, broncho-associated lymphoid tissue; CD, cluster of differentiation; GALT, gut-associated lymphoid tissue; MHC, major histocompatibility complex; NALT,
nasal-associated lymphoid tissue; NK, natural killer.
Immunovac-VP-4. Intranasal vaccination significantly increased
the level of surface markers of effector cells in the lymph nodes
of the NALT–BALT: Tγδ increased 32-fold (from 0.05 to 1.6%),
B1 increased 8-fold (from 0.21 to 1.7%), and CD19 (from 0.63
to 25.2%) and CD4 (from 3.5 to 13.7%) increased 39-fold and
3.9-fold, respectively. In the spleen, the level of Tγδ increased 16-
fold (from 0.17± 0.03% to 2.8± 0.02%) and the level of B1 (from
0.08 to 0.9%) increased 11-fold. In the GALT, all investigated values
increased to lesser extent in comparison with those in the spleen
and in the lymph nodes in the NALT–BALT. It is important to note
that the mice received a relatively low dose of vaccine intranasally
(total dose, 1500µg), which was only 3.75 times higher than the
subcutaneous dose (total dose, 400µg).
After three oral applications of the vaccine, all investigated
organs showed significant changes in cell numbers. In the GALT,
the relative number of Tγδ lymphocytes increased 45-fold (from
0.2 to 9.0%) and the number of B1 lymphocytes increased 117-fold
(from 0.15 to 11.7%). Only oral vaccination produced positive
changes in the natural killer cell population, which increased
47.5-fold (from 0.7 to 33.3%). In addition, the number of cells
with surface markers CD3, CD4, CD8, and CD19 increased signif-
icantly (11.5-, 17-, and 12.9-fold, respectively). In the NALT–BALT,
the number of Tγδ lymphocytes increased significantly (from
0.05 to 9.3%), as did the number of B1 lymphocytes (9.5-fold),
which is comparable with the results for intranasal vaccination.
However, oral vaccination did not produce strong changes in the
spleens of immunized mice, in contrast to intranasal vaccination:
the percentage of CD4, CD25, Tγδ, and B1 increased only six- to
eight-fold.
Subcutaneous vaccination led to a 240-fold increase in Tγδ
(from 0.05 to 12.0%) lymphocytes in NALT–BALT and to a
31.2-fold increase of Tγδ lymphocytes (from 0.17± 0.03% to
5.3± 0.5%) in the spleen. Also, the high increase in the level of
B1 lymphocytes in these organs compared with a much smaller
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increase in levels of other lymphocytes indicates that signifi-
cant activation of the innate immune system cells in the spleen
and lymph nodes in NALT–BALT was taking place. Intranasal
vaccination produced less-dramatic changes in the intestine.
CYTOTOXIC ACTIVITY OF NK CELLS
The cytotoxic effect of NK cells in vitro was assessed using the
NK-dependent tumor cell line K-562 (Table 2). Cytotoxic activity
significantly (p< 0.05) increased after only a single application of
the vaccine. After subcutaneous injection, cytotoxicity increased,
more in the spleen than in other organs, and was significantly
(p< 0.05) higher compared with cytotoxicity in control mice and
in the cells obtained from the lymphoid organs associated with the
respiratory and gastrointestinal tracts. That trend was maintained
after two subcutaneous injections of the antigens. Compared
with mucosal immunization, three doses of oral immunization
increased the cytotoxicity of spleen cells. In the NALT–BALT, there
was a significant (p< 0.05) increase in cytotoxicity even after a
single dose of the vaccine. Additional doses increased the cyto-
toxicity. In the GALT, there was a significant (p< 0.05) increase
in cytotoxicity after both subcutaneous and oral vaccination. The
highest degree of cytotoxicity occurred after oral immunization, in
cells obtained from lymph formations: 32.6± 3.2% after a single
dose and 75.4± 1.8% after three doses, which correlates with
the data presented in Table 1 showing a significant (p< 0.05)
increase in the percentage of NK cells after oral immunization
alone.
After repeated applications of the same antigens, the differ-
ence in results between immunization methods faded; however,
the expression of NK and CD4–NK cells in intestinal lymph still
persisted, but only after oral vaccination.
CYTOKINE PRODUCTION
Cytokine levels were measured after mucosal immunization with
a single dose of Immunovac-VP-4 versus levels after a single dose
of subcutaneously administered vaccine for IL-1β, IL-6, IL-4, IL-
10, IL-12, IL-5, tumor necrosis factor alpha (TNF-α), and IFN-γ
in mice sera. Eight hours after injection, the level of the follow-
ing cytokines significantly increased: IL-1β, IL-6, IL-12, and IL-5
(Table 3). However, their concentrations varied according to the
route of vaccine administration. Cytokine production was most
active after subcutaneous immunization, but mucosal immuniza-
tion also presented significant results (p< 0.05). There was no
significant difference in cytokine production between intranasal
and oral immunization.
No difference in levels of IL-10, IL-4, or TNF-α was
found among the various routes of vaccination. However, after
subcutaneous injection of Immunovac-VP-4, the sera showed a
fivefold increase in the level of IFN-γ compared with the control
animals.
Table 2 | Cytotoxic activity of mononuclear leukocytes against NK-dependent tumor cell line K562.
Method of immunization with immunovac-VP-4 Cytotoxicity (M ±m %) by tissue type
Spleen NALT and BALT GALT
1a 2b 1a 2b 1a 2b
Intranasally 20.3±1.3 12.0±0.1 19.5±2.5* 16.4±0.72* 6.8±0.4 8.4±0.8*
Orally 19.9±1.5 33.7±1.0* 11.2±0.7* 20.1±0.8* 32.6±3.2* 75.4±1.8*
Subcutaneously 38.6±3.1* 33.7±0.9* 15.8±1.5* 27.0±1.0* 14.5±0.7* 19.3±2.2*
Control (non-immunized) mice 22.3±2.8 18.3±1.2 6.2±0.8 7.7±0.72 3.1±0.4 2.0±1.1
aSingle dose of vaccine.
bThree vaccine doses nasally or orally and two doses subcutaneously.
*p<0.05 compared with control (t-test).
BALT, broncho-associated lymphoid tissue; GALT, gut-associated lymphoid tissue; NALT, nasal-associated lymphoid tissue; NK, natural killer.
Table 3 | Level of cytokines in mice sera after single injection of immunovac-VP-4.
Method of vaccine introduction Level of cytokines,M ±m (pg/mL)
IL-1β IL-6 IL-10 IL-12 IL-4 IL-5 IFN-γ TNF
Oral 17.8±0.6a 132±16.3a 37.5±2.8 12.5±1.5a 5.8±0.8 43.6±1.5a 1.7 7.5±1.1 30.5±3.1
Intranasal 18.2±0.7a 115±25.6a 39±3.3 13.2±1.2a 6.8±0.7 55.5±12.6a 2.2 7.3±0.5 33.7±2.1
Subcutaneous 68.3±3.2a 215±15.8a 41.2±4.5 38.6±2.7a 5.5±0.4 98.3±9.8a 3.8 36.6±2.8a 36.6±2.8
Control (non-immunized) mice 5.2±0.5 46.8±3.3 36.3±3.8 5.2±0.6 5.4±0.6 25.7±2.1 7.2±0.5 28.3±2.1
aThe difference between the control and experimental groups; p< 0.05 (t-test).
IL, interleukin; IFN, interferon.
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Multiple doses of Immunovac-VP-4 affected the expression of
cytokines in mice sera by 24 h after the last application, signif-
icantly increasing the quantity of IL-1β, IL-5, IL-6, and IL-12
with all routes of vaccine administration. There was a signifi-
cant increase in IFN-γ levels in that period even after a single
subcutaneous injection of the vaccine.
DISCUSSION
After recognizing that pathogen-derived TLRs program the activa-
tion of antigen-presenting cells (APC) immediately after interac-
tion with TLRs, Wolska et al. (13) showed that activation of TLR4
and TLR9 induces differentiation of Th1, while TLR2 activates
Th2, which leads to the shift in the Th1–Th2 system to Th2.
The activation TLR4 and TLR9 in the absence of the expres-
sion of TLR2 is one of the stages of the mechanism of mucosal
immunization that must be decoded, because at a sufficient
dose, the technique provides better protection and significantly
decreases the degree of immediate and delayed hypersensitivity in
comparison with subcutaneous administration (14).
Subcutaneous administration produced a significant increase
in TLR2, TLR4, and TLR9 levels in the spleen and in the NALT–
BALT, but no significant change in the expression of TLRs within
the intestinal mucosa. The level of receptors in the intestinal
mucosa did not exceed 1% of the levels found with subcuta-
neous immunization, whereas oral immunization produced TLR4
and TLR9 increases of 14.9± 1.47% and 13± 1.62%, respectively.
Intranasal vaccination also increased the level of TLR9.
It is noteworthy that oral immunization increased the expres-
sion of TLRs in all investigated organs, including the spleen. The
participation of the spleen in this process indicates the develop-
ment of not only local immunity, but also system immunity.
Our study produced the following findings:
• When mucosal vaccination is used, there is a prominent expres-
sion of TLR4 and TLR9 and an absence of the expression of
TLR2.
• When oral vaccination is used, there is significant expression of
TLRs in the GALT, NALT–BALT, and spleen.
• When intranasal vaccination was used in doses that induce a sig-
nificant increase in the expression of TLRs, this occurred only
in NALT–BALT, while subcutaneous administration resulted in
increased levels of TLRs in the NALT/BALT and spleen. How-
ever, subcutaneous administration did not increase the level of
TLRs in the GALT (an exception is TLR9). Similarly, subcu-
taneous injection does not induce the expression of TLR2 or
TLR4 in the NALT–BALT, spleen, or in the lymphoid apparatus
of the intestine; only TLR9 was expressed.
Hence, Immunovac-VP-4 evoked different pathways of cellular
activation depending on the method of application: the subcuta-
neous route increased the expression of TLR4, TLR9, and TLR2,
which led to further cellular differentiation in the direction of Th1
and to some degree in the direction of Th2. Expression of TLR4
and TLR9 after mucosal immunization predetermined the further
development of the immune response toward Th1, inducing the
production of interferon gamma (IFN-γ), thus suppressing the
synthesis of IL-4 and the likelihood of further development of
atopy.
An important feature of innate immunity activation is the
increase of differential markers on lymphocytes, costimulatory
molecules, and the APCs. This was revealed earlier in studies
of subcutaneous use of Immunovac-VP-4. In our current inves-
tigation, we used different immunization methods to elucidate
the features of MIS activation (15). Antigens of opportunistic
bacteria, independent of the injection technique used, actively
stimulate the innate immune system and result in the quick forma-
tion of non-specific resistance. Our investigation has shown that
innate and adaptive immunity activation is triggered by recog-
nition of pathogen-derived antigens by TLRs. Mucosal injection
with Immunovac-VP-4 in the lymphoid organs associated with the
mucosa and in the spleen engenders the expression of TLR4, and
TLR9, with further possible differentiation of T-helper cells via
the Th1 pathway. Activation of Th1 type cells accompanies IFN-γ
production, inhibiting the synthesis of IL-4 and further develop-
ment of atopy. It has been shown that subcutaneous injection of
the same antigens also leads to a significant increase in levels of
TLR2, leading to the further activation of Th1 and Th2. These data
indicate that mucosal immunization may significantly decrease the
degree of allergization by microorganisms (16).
The significance of TLR2 in sensitization that has recently been
confirmed by several investigations (17–20), demonstrated that a
polymorphism of the allele Ars7543708 TLR2 plays an important
role in regulating the production of immunoglobulin E (IgE). The
frequency of this mutant gene in the population, according to data
from those studies, is not more than 5%, but the gene is present in
7.9% of patients with allergic diseases. The involvement of TLR2
in the development of an allergic reaction, and the associated pro-
duction of IgE, suggests to investigate immune reactions resulting
from the use of different bacterial and viral agonists of TLRs, and
to determine the particular features of these administrations for
immune activation for different routes of antigen application.
The decreased risk of allergic sensitization by different vaccines
is the main advantage of mucosal vaccination over other methods,
especially in children. The continued growth in the prevalence
of allergic diseases and the lack of a safe, effective treatment for
them poses a large problem worldwide. Thus, the development of
mucosal vaccines and their widespread use may help decrease the
burden of allergic pathology worldwide.
Apart from different levels of TLR expression, the immunophe-
notype of activated or recruited lymphocytes is also dependent
on the method of vaccine application. Even a single dose of the
vaccine Immunovac-VP-4 leads to increased levels of Tγδ and
B1 lymphocytes in all mucosal methods of antigen introduction,
and additional doses increase the levels even more. It is known
that these cells are the major components of the MIS, charac-
terized by the ability to recognize bacterial and viral ligands,
without costimulatory signals and previous processing by other
immune cells. This ability allows for rapid protection from dif-
ferent pathogens and makes it possible to decode how antigens
introduced through mucosal immunization produce less sensiti-
zation than other methods, in such a way that interaction between
these cells increases the production of antibodies IgM and IgA, but
not of IgE.
Our findings confirm that mucosa-associated lymphoid tissue
is the main systemic immunity organ (21–23). In view of the fact
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that the mucosa functions as the first line of protection against
pathogens, Tγδ and B1 lymphocytes play the most prominent
role in immunity, as they are capable to recognize the PAMPs
of microorganisms without previous processing and presentation
to MHC class II-restricted T lymphocytes.
All distinct vaccination routes showed some features in com-
mon. The increase of B1 and Tγδ lymphocytes was probably not
only due to the vaccination route, but also to the character of the
antigens used, which were processed in the cells without previ-
ous participation of MHC class II-restricted CD4 lymphocytes.
It is noteworthy that the expression of NK cell markers involves
the participation of MHC class II-restricted CD4 lymphocytes. We
found that the expression of NK markers took place to a significant
degree only when oral vaccination was used.
It is important to note that mucosal vaccination not only signif-
icantly increased lymphocyte activation in NALT–BALT and GALT,
but also significantly increased the level of surface markers in the
spleen, which is evidence of the development of not only mucosal
immunity but also systemic immunity when this method was used.
Only oral vaccination produced a significant increase in the num-
ber of NK cells, which are the main components of innate and
adaptive immunity that correlate with maximum cytotoxicity in
mononuclear leukocytes obtained from GALT. Although we found
that cytokine production was increased by all three immunization
routes, it was most intensive after subcutaneous injection.
In conclusion, our data demonstrate a high degree of acti-
vation of innate immunity effectors that is associated with the
expression of TLRs, the emergence of a significant number of cells
with differential surface marker molecules, the proliferation of the
key effectors of mucosal immunity (Tγδ, B1, and NK cells), and
an increase in cytotoxicity and cytokine production. In view of
our findings, it is apparent that the development of a single-dose
mucosal vaccine and associated vaccines should be a priority in
contemporary vaccinology.
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